90 related articles for article (PubMed ID: 17039656)
1. Induction of lesional and circulating leukocyte apoptosis by infliximab in a patient with moderate to severe psoriasis.
Malaviya R; Sun Y; Tan JK; Magliocco M; Gottlieb AB
J Drugs Dermatol; 2006 Oct; 5(9):890-3. PubMed ID: 17039656
[TBL] [Abstract][Full Text] [Related]
2. Programmed cell death of keratinocytes in infliximab-treated plaque-type psoriasis.
Krüger-Krasagakis S; Galanopoulos VK; Giannikaki L; Stefanidou M; Tosca AD
Br J Dermatol; 2006 Mar; 154(3):460-6. PubMed ID: 16445776
[TBL] [Abstract][Full Text] [Related]
3. Influence of infliximab on keratinocyte apoptosis in psoriasis patients.
Raho G; Vena GA; Bizzoca A; Cassano N; Garofalo E; Congedo M; Gennarini G
Immunopharmacol Immunotoxicol; 2011 Mar; 33(1):227-31. PubMed ID: 20507213
[TBL] [Abstract][Full Text] [Related]
4. Etanercept induces apoptosis of dermal dendritic cells in psoriatic plaques of responding patients.
Malaviya R; Sun Y; Tan JK; Wang A; Magliocco M; Yao M; Krueger JG; Gottlieb AB
J Am Acad Dermatol; 2006 Oct; 55(4):590-7. PubMed ID: 17010737
[TBL] [Abstract][Full Text] [Related]
5. Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis.
Reich K; Nestle FO; Wu Y; Bala M; Eisenberg D; Guzzo C; Li S; Dooley LT; Griffiths CE
Eur J Dermatol; 2007; 17(5):381-6. PubMed ID: 17673380
[TBL] [Abstract][Full Text] [Related]
6. [Sequential histological and immunohistochemical assessment of proliferation and apoptotic markers during treatment of psoriasis with antitumor necrosis factor alpha (infliximab)].
Gómez-Mateo C; Avalos-Peralta SP; Ríos-Martín JJ; Carrizosa-Esquivel AM; González-Cámpora R; Camacho-Martínez F
Actas Dermosifiliogr; 2009 Jun; 100(5):420-4. PubMed ID: 19558920
[TBL] [Abstract][Full Text] [Related]
7. The role of lesional T cells in recalcitrant psoriasis during infliximab therapy.
Bovenschen HJ; Van De Kerkhof PC; Gerritsen WJ; Seyger MM
Eur J Dermatol; 2005; 15(6):454-8. PubMed ID: 16280298
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of the inhibitor of apoptosis protein survivin in keratinocytes and endothelial cells in psoriasis skin following infliximab therapy.
Markham T; Mathews C; Rogers S; Mullan R; Bresnihan B; Fitzgerald O; Veale DJ; Fearon U
Br J Dermatol; 2006 Dec; 155(6):1191-6. PubMed ID: 17107388
[TBL] [Abstract][Full Text] [Related]
9. Infliximab monotherapy in psoriasis: a case of rapid clinical and histological response.
Vincek V; Jacob SE; Nassiri M; Herbert LM; Nadji M; Kerdel FA
Int J Dermatol; 2004 Apr; 43(4):303-8. PubMed ID: 15090021
[TBL] [Abstract][Full Text] [Related]
10. Long-term maintenance treatment of moderate-to-severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort.
Dalaker M; Bonesrønning JH
J Eur Acad Dermatol Venereol; 2009 Mar; 23(3):277-82. PubMed ID: 19207642
[TBL] [Abstract][Full Text] [Related]
11. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.
Menter A; Feldman SR; Weinstein GD; Papp K; Evans R; Guzzo C; Li S; Dooley LT; Arnold C; Gottlieb AB
J Am Acad Dermatol; 2007 Jan; 56(1):31.e1-15. PubMed ID: 17097378
[TBL] [Abstract][Full Text] [Related]
12. Antitumour necrosis factor-alpha chimeric antibody (infliximab) inhibits activation of skin-homing CD4+ and CD8+ T lymphocytes and impairs dendritic cell function.
Bedini C; Nasorri F; Girolomoni G; Pità Od; Cavani A
Br J Dermatol; 2007 Aug; 157(2):249-58. PubMed ID: 17489975
[TBL] [Abstract][Full Text] [Related]
13. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity.
Poulalhon N; Begon E; Lebbé C; Lioté F; Lahfa M; Bengoufa D; Morel P; Dubertret L; Bachelez H
Br J Dermatol; 2007 Feb; 156(2):329-36. PubMed ID: 17223874
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy of treatment with infliximab in patients with moderate-severe psoriasis and high needs of therapy. A retrospective study of 43 patients].
Puig L
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():30-5. PubMed ID: 19080989
[TBL] [Abstract][Full Text] [Related]
15. Infliximab and nephrotic syndrome.
Chin G; Luxton G; Harvey JM
Nephrol Dial Transplant; 2005 Dec; 20(12):2824-6. PubMed ID: 16204273
[TBL] [Abstract][Full Text] [Related]
16. Life-threatening pustular and erythrodermic psoriasis responding to infliximab.
Lewis TG; Tuchinda C; Lim HW; Wong HK
J Drugs Dermatol; 2006 Jun; 5(6):546-8. PubMed ID: 16774108
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study.
Rigopoulos D; Gregoriou S; Stratigos A; Larios G; Korfitis C; Papaioannou D; Antoniou C; Ioannides D
Br J Dermatol; 2008 Aug; 159(2):453-6. PubMed ID: 18565184
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of infliximab for severe recalcitrant psoriasis after 6 weeks of treatment.
DE Oliveira JP; Levy A; Morel P; Guibal F
J Dermatol; 2008 Sep; 35(9):575-80. PubMed ID: 18837702
[TBL] [Abstract][Full Text] [Related]
19. Review and expert opinion on prevention and treatment of infliximab-related infusion reactions.
Lecluse LL; Piskin G; Mekkes JR; Bos JD; de Rie MA
Br J Dermatol; 2008 Sep; 159(3):527-36. PubMed ID: 18627374
[TBL] [Abstract][Full Text] [Related]
20. Infliximab.
Winterfield LS; Menter A
Dermatol Ther; 2004; 17(5):409-26. PubMed ID: 15379776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]